Search PubMed⌕ Search

Biomedical subjects

O I Afanas'eva

Publications and source records attributed to O I Afanas'eva.

12 recordsLinked to original sources
PubMed2002

[Method of quantitative analysis of beta2-microglobulin in human blood].

A simple and economic method of radial immunodiffusion is developed for diagnostic measurements of beta 2-microglobulin in human serum. Human serum and plasma concentrations of beta 2-microglobulin can be measured sufficiently accurately; the results are reproducible. The reproducibility and addictiveness of the method were evaluated. The error of the method is no more than 15% (3-36 mg/liter), which is permissible for methods of this type.

Humans↗
PubMed2002

[Effect of hormone replacement therapy on blood serum lipids in postmenopausal women with type 2 diabetes].

There are limited data concerning influence of hormone replacement therapy (HRT) on lipid profile in women with type 2 diabetes. Aim of the study was to compare changes of blood lipids during HRT in postmenopausal women with and without type 2 diabetes. Seventy seven women included in the study were assigned to 1 of 4 groups, basing on being diabetic or nondiabetic, and further subdivided into users of estrogen alone (ERT), and of estrogen plus progestin (EPRT). Effect of 6-month ERT (oral estradiol valerate 2 mg/day) and EPRT (oral estradiol valerate 2 mg/day sequentially combined with cyproterone acetate 1 mg/day) on total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), triglycerides and lipoprotein (a) [Lp(a)] was separately assessed. EPRT and ERT caused decrease in LDL-C by 15% and 12%, and increase in HDL-C by 12% and 13%, respectively, in patients with diabetes (p<0.05 in all cases). LDL-C decreased by 11% and 15%, respectively, in women without diabetes (p<0.05 in all cases). Lp(a) was also reduced 25% with EPRT (p<0.01) and ERT (p<0.05). HDL-C increased 10% (p<0.05) with ERT but remained unchanged with EPRT. In conclusion, changes in all lipid parameters except Lp(a) caused by ERT and EPRT were comparable in postmenopausal women with and without type 2 diabetes.

Aged↗
PubMed2002

[Lipoprotein (a) and ischemic heart disease in patients with hypertensive disease].

Relationship between level of lipoprotein (a) and presence of ischemic heart disease (IHD) was studied in 191 patients with hypertensive disease (essential hypertension) (112 men, 79 women, age 56.9-/+10.6 years) and 33 patients with normal blood pressure (23 men, 10 women, age 50.8-/+11.0 years). Concentration of lipoprotein (a) in men with hypertension and IHD (n=62) was significantly higher than in men with hypertension without IHD (n=50) (median 19 and 9 mg/dl, respectively, p=0.02). Women with hypertension and with (n=23) and without (n=56) IHD had similar blood levels of lipoprotein (a) (median 13 and 15 mg/dl, respectively, p=0.89). Difference in lipoprotein (a) levels between patients with hypertensive disease and those with normal blood pressure was not significant (median 14 and 10 mg/dl, respectively, p=0.50).

Adult↗
PubMed2002

[Lipoprotein(a) and Apo-A isoforms in patients with intermittent claudication].

AIM: To study a correlation between lipoprotein(a) [LP(a)], as well as the phenotype of apoprotein(a) [apo(a)] and the presence of intermittent claudication (IC). MATERIALS AND METHODS: The study included 25 patients (9 females, 16 males; mean age, 63.4 +/- 8.2 years) and 50 individuals (21 females, 29 males; mean age, 61.3 +/- 6.1 years) of a control group. RESULTS: In the patients, the level of LP(a) was 3 times higher than in the controls (median 39 and 13 mg/dl, respectively; p < 0.01). The low molecular-weight phenotypes of apo(a) occurred significantly more frequently in the patients than those in the controls (62 and 28%, respectively; p = 0.02). CONCLUSION: Multifactorial analysis has shown that the level of Lp(a) is an independent and important factor associated with the presence of IC.

Aged↗
PubMed2001

Immunosorbent for removal of b2-microglobulin from human blood plasma.

Immunosorbent removing beta2-microglobulin from human blood plasma was synthesized on the basis of sheep monospecific polyclonal antibodies to beta2-microglobulin and conditions ensuring effective regeneration of the immunosorbent for its repeated use were selected. Relationships between adsorption capacity and the volume of immobilized ligand, antigen concentration in the solution, and duration of incubation were studied. The adsorbent can be used for effective and specific removal of beta2-microglobulin from the plasma of patients on chronic hemodialysis.

Adsorption↗
PubMed2000

[Association of lipoprotein(a) and apolipoprotein(a) phenotypes with coronary and carotid atherosclerosis in CHD men].

AIM: To evaluate in a case-control cross-sectional study whether lipoprotein(a) concentration and apo(a) phenotypes are associated with the presence and severity of coronary and carotid atherosclerosis. MATERIALS AND METHODS: We have examined 198 male CHD patients (mean age 53 +/- 8) years) with stenosis more than 50% at least in one main coronary artery or its major branches. Duplex scanning was performed in 168 patients to assess the degree of carotid atherosclerosis. Seventy six apparently healthy men (mean age 39 +/- 9 years) formed the control group. Lp(a) concentration was measured by ELISA, apo(a) phenotyping was performed by immunoblotting. RESULTS: Lp(a) level was significantly higher in cases compared to controls: 37 +/- 31 mg/dl vs. 18 +/- 27 mg/dl, p < 0.05. Patients had low-molecular weight apo(a) phenotypes more frequently than controls: 46% vs. 29%, p = 0.01. Patients aged 45 years and younger had low-molecular weight apo(a) phenotypes more frequently than older ones (65% vs. 42%, p < 0.05) and controls (65% vs. 29%, respectively, p = 0.001). High Lp(a) level and low-molecular weight apo(a) phenotypes correlated with presence and number of coronary occlusions. CONCLUSION: There was association between Lp(a) level, low-molecular weight apo(a) phenotypes and presence, severity, extension of carotid atherosclerosis. No differences in distribution of other CHD risk factors among all subgroups of patients were found.

Adult↗
PubMed1998

[Chemotherapeutics for treatment of influenza and other viral respiratory tract infections in children].

Therapeutic efficacy of remantadine and arbidole was studied in the clinical and laboratory observation of pediatric in- and outpatients with grippe and mixed viral infections in various seasonal epidemic. In the trial of remantadine 742 school children and 60 children at the age of 3 to 6 years with type A, B or A + B grippe, grippe in association with other acute viral respiratory tract infections or acute viral respiratory tract infections of nongrippe etiology were observed. 402 and 400 of them were given remantadine and placebo respectively. The drug was used in a single dose of 1.5 mg/kg body weight 3 times a day for 3 days. In the trial of arbidole 158 children at the age of 1 to 14 years with type A grippe, grippe + acute viral respiratory tract infection and acute viral respiratory tract infection of nongrippe etiology were observed. The arbidole daily dose of 10 mg/kg body weight was given in 4 portions for 5 days. Both the drugs were shown to be therapeutically efficient in all the grippe types and acute viral respiratory tract infections. The highest efficacy was observed when the use of the drugs was started at the early stages. With the use of the drugs the periods of fever, other intoxication signs and virus isolation decreased. No adverse reactions were recorded. The drugs had no inhibitory effect on the cellular and humoral immunity and on production of antiviral antibodies. The dynamics of the indices of the cellular immunity and macrophages confirmed the arbidole immunostimulating action.

Adolescent↗
PubMed1992

[A comparison of 3 methods of lipoprotein (a) isolation from human plasma].

Three methods for purification of lipoprotein (a) [Lp(a)] from human plasma were compared. Method I: two-stage ultracentrifugation with subsequent gel-filtration of Lp(a) containing fractions (1.063-1.090 g/ml) on Sepharose CL-4B. Method II: ultracentrifugation followed by affinity chromatography of plasma fraction (1.063 g/ml) on anti-apoB sorbent. Method III: affinity chromatography of the whole plasma on anti-apo(a) sorbent. The Lp(a) yield of these methods is 35, 54 and 41%, respectively. The method III is preferable of these three because it permitted high purification of a large amount of Lp(a) by single-step chromatography.

Chromatography, Affinity↗